Inovalon Holdings (INOV) : The consensus on Inovalon Holdings (INOV) based on 7 analyst recommendation on the company stock is 2.9, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 2 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.
Inovalon Holdings (INOV) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $20 and the lowest price target forecast is $11. The average forecast of all the analysts is $15.2 and the expected standard deviation is $3.27.
Also, In a research note released to the investors, KeyBanc maintains its rating on Inovalon Holdings (NASDAQ:INOV).The analysts at the brokerage house have a current rating of Overweight on the shares. In a recent information released to the investors, KeyBanc lowers the new price target from $26 per share to $20 per share. The rating by the firm was issued on August 16, 2016.
Inovalon Holdings (NASDAQ:INOV): After opening at $15.79, the stock dipped to an intraday low of $15.72 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $16.2232 and the buying power remained strong till the end. The stock closed at $16.12 for the day, a gain of 1.96% for the day session. The total traded volume was 493,380. The stocks close on the previous trading day was $15.81.
Inovalon Holdings, Inc. is a technology company. The Company combines advanced cloud-based data analytics and data-driven intervention platforms to provide services for health plans, hospitals, physicians, patients, pharmaceutical companies and researchers. Through its datasets, integration technologies, predictive analytics and subject matter expertise, the Company delivers platforms. Its analytics identify gaps in care, quality, data integrity, and financial performance, while providing clients with capabilities to resolve these gaps. The Companys data analytics and intervention platforms consist of four primary components: data integration, advanced analytics, intervention platforms and business processing. This system manages the process of defining and configuring industry data feeds from its clients and partners, including electronic health records, laboratory, pharmacy, patient reported, claims, paper based medical records, biometric, and hospital data feeds.